Fundraising Fox
Accipiter Biosciences
Seattle, US · Founded 2023 · Delaware corporation · 26 employees on LinkedIn · 6 known investors
Find your way into Accipiter Biosciences
Sign up to see every warm intro you have to Accipiter Biosciences
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Accipiter Biosciences team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Accipiter Biosciences uses computational protein design to develop de novo, single-agent protein therapies that engage multiple cell-surface receptors at once, functioning as agonists. Its platform targets complex conditions such as autoimmune disorders and cancer as an alternative to traditional combination therapies.
Founders & leadership
Accipiter Biosciences was founded in 2023 by Matthew Bick.
MB
Matthew BickCEO and co-founderMatthew Bick is a biotechnology executive with more than 20 years in leadership and research roles focused on therapeutics design, computational protein engineering, and structural biology.
JC
HD
Hector De Jesus Rincon AranoNamed on SEC filing
HR
Heather RedmanNamed on SEC filing
RS
Randall SchatzmanNamed on SEC filing
Board
JA
Jose Antonio Mesa CejudoBoard director
HG
JG
Jiaping GuBoard director
Investors · 6
Flying Fish Ventureslisted by Flying Fish VenturesSeattle · $500K – $5M
How we know: Flying Fish Ventures's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
Argonautic VenturesreportedNew York · $5M
How we know: offering press articles · Not right? Tell us
Columbus Venture PartnersreportedValenciavia Jose Mesa · inferred
How we know: a partner's Signal profile · offering press articles · Not right? Tell us
Pack VenturesreportedSeattlevia Ken Horenstein · inferred
How we know: offering press articles · Not right? Tell us
WRF CapitalreportedSeattle · $100K – $2M
How we know: offering press articles · Not right? Tell us
Funding
SEC filings, press & company announcements$37.4M disclosed across 4 rounds · 2023–2026
- $12.7MSeed FinancingNov 2025 · 2 sourcesSource ↗
▶$10.5MraisedJul 2026 · 9 investors · BiotechnologyRule 506(b)
▶$10.5MraisedJul 2026 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Matthew BickExecutive Officer, Director, Promoter
- Hector De Jesus Rincon AranoExecutive Officer, Director, Promoter
- Javier CastellanosExecutive Officer, Director, Promoter
- Heather RedmanDirector
- Randall SchatzmanDirector
- William CanestaroExecutive Officer
- Jose Antonio Mesa CejudoDirector
- Offering amount
- $10.5M
- Amount sold
- $10.5M
- First sale
- Jul 2026
- Incorporated
- Corporation, Delaware, 2023
- Federal exemptions
- 06b
▶$13.6MraisedSep 2025 · 15 investors · Other TechnologyRule 506(b)
▶$13.6MraisedSep 2025 · 15 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Heather GorhamDirector
- Jose Antonio Mesa CejudoDirector
- Jiaping GuDirector
- Matthew BickExecutive Officer, Director, Promoter
- Javier CastellanosExecutive Officer, Director, Promoter
- Hector De Jesus Rincon AranoExecutive Officer, Promoter
- Offering amount
- $13.7M
- Amount sold
- $13.6M
- First sale
- May 2024
- Incorporated
- Corporation, Delaware, 2023
- Federal exemptions
- 06b
▶$650KraisedMay 2023 · 6 investors · Other TechnologyRule 506(b)
▶$650KraisedMay 2023 · 6 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Matthew BickExecutive Officer, Director, Promoter
- William ArthurExecutive Officer, Director, Promoter
- Javier CastellanosExecutive Officer, Director, Promoter
- Hector AranoExecutive Officer, Director, Promoter
- Offering amount
- $1M
- Amount sold
- $650K
- First sale
- Apr 2023
- Incorporated
- Corporation, Delaware, 2023
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Accipiter Biosciences went on to found or lead other companies.
Related companies · 7
IQVIAIQVIA is a healthcare data and technology company that supports life sciences organizations in research, clinical development, and commercialization of medicines and medical solutions.
Ambit Biosciences CorporationAmbit Biosciences was a San Diego biopharmaceutical company developing small-molecule kinase inhibitors, including quizartinib, a FLT3 inhibitor for acute myeloid leukemia.
Kite PharmaKite develops CAR T-cell therapies that engineer a patient's own immune cells to target and destroy cancer cells. The company focuses on cell therapy treatments for cancers such as diffuse large B-cell lymphoma.
Avidity BiosciencesAvidity Biosciences develops Antibody Oligonucleotide Conjugates (AOCs) that combine monoclonal antibody specificity with oligonucleotide precision for targeted delivery of RNA therapeutics to treat rare genetic muscle diseases. The company has three clinical-stage programs targeting myotonic dystrophy type 1, facioscapulohumeral muscular dystrophy, and Duchenne muscular dystrophy.
Aro BiotherapeuticsAro Biotherapeutics develops tissue-targeted genetic medicines using a proprietary protein technology called Centyrins. The company builds a wholly-owned pipeline of Centyrin-based therapeutic candidates and partners with industry to enable tissue-specific targeting of therapeutics across a range of diseases.
Fortis Life SciencesFortis Life Sciences develops and manufactures Bethyl-branded ELISA kits and related reagents, buffers, and antibodies for detecting target proteins in research and diagnostic applications. The kits cover human and veterinary targets and are made in the USA using the company's own antibodies.
C4 TherapeuticsC4 Therapeutics develops targeted protein degradation medicines aimed at treating disease. The company works in the biotechnology and drug development space.
Companies working in the same space as Accipiter Biosciences.
In the news
Frequently asked questions
- What does Accipiter Biosciences do?
- Accipiter Biosciences uses computational protein design to develop de novo, single-agent protein therapies that engage multiple cell-surface receptors at once, functioning as agonists. Its platform targets complex conditions such as autoimmune disorders and cancer as an alternative to traditional combination therapies.
- Who founded Accipiter Biosciences?
- Accipiter Biosciences was founded by Matthew Bick in 2023.
- Who are Accipiter Biosciences's investors?
- Accipiter Biosciences's investors include Creative Destruction Lab (CDL), Flying Fish Ventures, Argonautic Ventures, Columbus Venture Partners, Pack Ventures, WRF Capital.
- How much funding has Accipiter Biosciences raised?
- Accipiter Biosciences has disclosed $37.4M raised across 4 rounds.
- Where is Accipiter Biosciences headquartered?
- Accipiter Biosciences is headquartered in Seattle, US.